Professional Services News / DrugPipeline.net

Ovarian Cancer - Pipeline Review, H1 2017; New Report Launched

Via: ReleaseWire

Updated 2:25 PM CDT, Tue, September 12,2017

DrugPipeline.net has announced the addition of “Ovarian Cancer - Pipeline Review, H1 2017” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWIRE) -- 09/12/2017 -- Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Publisher's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 2027 pages "Ovarian Cancer - Pipeline Review, H1 2017" report covers Introduction, Ovarian Cancer - Overview, Ovarian Cancer - Therapeutics Development, Ovarian Cancer - Therapeutics Assessment, Ovarian Cancer - Drug Profiles, Appendix. The report covered companies are - 3-V Biosciences Inc, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Adaptimmune Therapeutics Plc, Adgero Biopharmaceuticals Holdings Inc, Aduro BioTech Inc, Advanced Accelerator Applications SA, Advanced Cancer Therapeutics LLC, Advantagene Inc, Advenchen Laboratories LLC, Aeterna Zentaris Inc, Alethia Biotherapeutics Inc, Alkermes Plc, Almac Discovery Ltd, Alpha Cancer Technologies Inc, Alteogen Inc, Altor BioScience Corp

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/ovarian-cancer-pipeline-review-h1-2017

Find all Oncology Reports at - http://www.drugpipeline.net/catalog/oncology

Related Reports;

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017; visit at - http://www.drugpipeline.net/global-markets-direct/opioid-induced-bowel-dysfunction-obd-or-oibd-pipeline-review-h1-2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017; visit at - http://www.drugpipeline.net/global-markets-direct/acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-0

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit:
http://www.sbwire.com/press-releases/ovarian-cancer-pipeline-review-h1-2017-new-report-launched-861454.htm

Media Relations Contact
Sudeep Chakravarty
1-302-703-9904
Email: Click to Email Sudeep Chakravarty
Web: http://www.drugpipeline.net/global-markets-direct/ovarian-cancer-pipeline-review-h1-2017